Rezpegaldesleukin Shows Sustained Benefit in Moderate-to-Severe Atopic Dermatitis in Phase 2 b trial
The phase 2b REZOLVE-AD trial enrolled 393 adults with moderate-to-severe atopic dermatitis across approximately 110 global ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4 Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a ...
Atopic dermatitis imposes a significant financial burden, costing over $4 billion annually, with federal assistance programs like SNAP improving healthcare affordability. A study using NHIS data found ...
Board-certified dermatologist, Dr. Sandra Lee, widely known as Dr. Pimple Popper, among others, details her journey with mild-moderate atopic dermatitis, the most common form of eczema, and her ...
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results